Skip to main content


Be confident that your patient care is up to date

Register now and start receiving our tailored medical education content from April. You can also secure your place for the first live webinar.

IN FOCUS | JAK inhibitors

Close up of young woman taking in pill

18-10-2022 | Psoriatic arthritis | News

Support for JAK inhibitors as ‘drug of choice’ for patients with PsA and significant joint disease

JAK inhibitors show promise for the treatment of moderate-to-severe psoriasis and psoriatic arthritis, finds a systematic review and meta-analysis of more than 6000 patients.

IN FOCUS | COVID-19 & rheumatic disease

Doctor with stethoscope and glowing coronavirus cell - medicine and innovation concept.

24-10-2022 | COVID-19 | News

Prophylactic antivirals may help prevent symptomatic COVID-19 in rituximab-treated patients

Pre-exposure prophylaxis with tixagevimab and cilgavimab may be an effective strategy to prevent symptomatic SARS-CoV-2 infection among people with rheumatic diseases treated with rituximab, suggest findings from a real-world study.

IN FOCUS | Inflammatory arthritis

Doctor holding virtual heart in hand. - healthcare concept

07-12-2022 | Rheumatoid arthritis | News

Similar reduction in CV risk with different add-on RA treatments

Among patients with active rheumatoid arthritis, adding tumor necrosis factor inhibitors to methotrexate is associated with a similar reduction in vascular inflammation to that seen with add-on sulfasalazine plus hydroxychloroquine, suggest findings from a randomized controlled trial.

IN FOCUS | Gout and crystal arthropathies

Man with painful and swollen right foot due to gout inflammation (symbolic image with model)

04-08-2022 | Gout | News

Gout flares linked to temporary increase in cardiovascular risk

Gout flares are associated with an increased risk for cardiovascular events in the following 120 days, study findings suggest.

IN FOCUS | Lupus

Close up of medical disposable syringe and vial

14-11-2022 | ACR 2022 | Conference coverage | News

Phase 3 trial supports add-on telitacicept for SLE

Addition of the recombinant fusion protein telitacicept to standard care may reduce disease activity and is well tolerated in people with systemic lupus erythematosus, research suggests.